玻璃体内注射抗vegf药物与聚维酮碘与氯己定水消毒后眼内炎的发生率。

IF 4.4 Q1 OPHTHALMOLOGY
Brandon Bates, John Fitzpatrick, Caroline Rosanky, Jared Moon, Edward Wood, Philip Storey
{"title":"玻璃体内注射抗vegf药物与聚维酮碘与氯己定水消毒后眼内炎的发生率。","authors":"Brandon Bates, John Fitzpatrick, Caroline Rosanky, Jared Moon, Edward Wood, Philip Storey","doi":"10.1016/j.oret.2025.03.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the incidence of post injection endophthalmitis (PIE) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in eyes prepared with topical 5% povidone-iodine (PI) or 0.05% aqueous chlorhexidine (AqCHX) as antisepsis.</p><p><strong>Design: </strong>Retrospective, single-center, comparative cohort study PARTICIPANTS: Individuals who received at least one intravitreal anti-VEGF injection with use of PI or AqCHX as antisepsis.</p><p><strong>Methods: </strong>For all patients receiving intravitreal anti-VEGF injections at Austin Retina Associates between March 1, 2015 and November 1, 2023, all injections and cases of suspected PIE were identified with billing codes and confirmed with review of electronic medical record data. Eyes that presented following injection with pain and/or decreased vision warranting treatment with intravitreal antibiotics were considered suspected PIE cases. Eyes were grouped based on preparation with PI or AqCHX.</p><p><strong>Main outcome measures: </strong>The primary outcomes were incidence of suspected and culture-positive PIE and visual acuity at 3 months post endophthalmitis.</p><p><strong>Results: </strong>A total of 302,474 intravitreal injections were administered during the study period. Within the PI group, 59 cases of suspected PIE occurred following 267,190 injections (0.022%; 1 in 4,529 injections) compared to 5 cases following 35,284 injections (0.014%; 1 in 7,057 injections) in the AqCHX group (p=0.34). For the PI group, there were 10 culture-positive PIE cases (0.0037%, 1 in 26,719 injections) compared to 0 cases in the AqCHX group (p=0.25). At 3-months post-infection, average visual acuity in the PI group was 0.97 (∼20/200) and 1.4 (∼20/500) in the AqCHX group (p=0.41). When controlling for prefilled syringe status, there was no difference in rates of PIE between antisepsis groups (p=0.23).</p><p><strong>Conclusions: </strong>The incidence of endophthalmitis following intravitreal injection is low with no difference in the rates of infection with eyes prepared with topical PI compared to AqCHX. Topical AqCHX is a safe and effective antiseptic alternative to PI for the prevention of endophthalmitis following intravitreal injection.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Endophthalmitis Incidence After Intravitreal Injection of Anti-VEGF Agents with Povidone-Iodine vs. Aqueous Chlorhexidine Antisepsis.\",\"authors\":\"Brandon Bates, John Fitzpatrick, Caroline Rosanky, Jared Moon, Edward Wood, Philip Storey\",\"doi\":\"10.1016/j.oret.2025.03.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the incidence of post injection endophthalmitis (PIE) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in eyes prepared with topical 5% povidone-iodine (PI) or 0.05% aqueous chlorhexidine (AqCHX) as antisepsis.</p><p><strong>Design: </strong>Retrospective, single-center, comparative cohort study PARTICIPANTS: Individuals who received at least one intravitreal anti-VEGF injection with use of PI or AqCHX as antisepsis.</p><p><strong>Methods: </strong>For all patients receiving intravitreal anti-VEGF injections at Austin Retina Associates between March 1, 2015 and November 1, 2023, all injections and cases of suspected PIE were identified with billing codes and confirmed with review of electronic medical record data. Eyes that presented following injection with pain and/or decreased vision warranting treatment with intravitreal antibiotics were considered suspected PIE cases. Eyes were grouped based on preparation with PI or AqCHX.</p><p><strong>Main outcome measures: </strong>The primary outcomes were incidence of suspected and culture-positive PIE and visual acuity at 3 months post endophthalmitis.</p><p><strong>Results: </strong>A total of 302,474 intravitreal injections were administered during the study period. Within the PI group, 59 cases of suspected PIE occurred following 267,190 injections (0.022%; 1 in 4,529 injections) compared to 5 cases following 35,284 injections (0.014%; 1 in 7,057 injections) in the AqCHX group (p=0.34). For the PI group, there were 10 culture-positive PIE cases (0.0037%, 1 in 26,719 injections) compared to 0 cases in the AqCHX group (p=0.25). At 3-months post-infection, average visual acuity in the PI group was 0.97 (∼20/200) and 1.4 (∼20/500) in the AqCHX group (p=0.41). When controlling for prefilled syringe status, there was no difference in rates of PIE between antisepsis groups (p=0.23).</p><p><strong>Conclusions: </strong>The incidence of endophthalmitis following intravitreal injection is low with no difference in the rates of infection with eyes prepared with topical PI compared to AqCHX. Topical AqCHX is a safe and effective antiseptic alternative to PI for the prevention of endophthalmitis following intravitreal injection.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2025.03.022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:观察用5%聚维酮碘(PI)或0.05%氯己定(AqCHX)配制的抗血管内皮生长因子(VEGF)药物玻璃体腔内注射后眼内炎(PIE)的发生率。设计:回顾性、单中心、比较队列研究参与者:接受至少一次玻璃体内抗vegf注射并使用PI或AqCHX作为防腐剂的个体。方法:对2015年3月1日至2023年11月1日在Austin Retina Associates接受玻璃体内抗vegf注射的所有患者,使用账单代码识别所有注射和疑似PIE病例,并通过审查电子病历数据进行确认。注射后出现疼痛和/或视力下降,需要玻璃体内抗生素治疗的眼睛被认为是疑似PIE病例。根据PI或AqCHX的制备方法对眼进行分组。主要指标:主要指标为眼内炎后3个月疑似及培养阳性PIE的发生率及视力。结果:在研究期间共进行了302,474次玻璃体内注射。在PI组中,267,190次注射后出现59例疑似PIE (0.022%;4529次注射中有1例),而35284次注射中有5例(0.014%;1 / 7057) (p=0.34)。PI组有10例PIE培养阳性(0.0037%,1 / 26,719次注射),AqCHX组为0例(p=0.25)。感染后3个月,PI组的平均视力为0.97 (~ 20/200),AqCHX组的平均视力为1.4 (~ 20/500)(p=0.41)。在控制预充注射器状态时,两组间PIE发生率无差异(p=0.23)。结论:玻璃体内注射后眼内炎的发生率较低,与AqCHX相比,外用PI制备的眼睛感染发生率无差异。外用AqCHX是一种安全有效的替代PI的防腐剂,用于预防玻璃体内注射后的眼内炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Endophthalmitis Incidence After Intravitreal Injection of Anti-VEGF Agents with Povidone-Iodine vs. Aqueous Chlorhexidine Antisepsis.

Purpose: To evaluate the incidence of post injection endophthalmitis (PIE) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in eyes prepared with topical 5% povidone-iodine (PI) or 0.05% aqueous chlorhexidine (AqCHX) as antisepsis.

Design: Retrospective, single-center, comparative cohort study PARTICIPANTS: Individuals who received at least one intravitreal anti-VEGF injection with use of PI or AqCHX as antisepsis.

Methods: For all patients receiving intravitreal anti-VEGF injections at Austin Retina Associates between March 1, 2015 and November 1, 2023, all injections and cases of suspected PIE were identified with billing codes and confirmed with review of electronic medical record data. Eyes that presented following injection with pain and/or decreased vision warranting treatment with intravitreal antibiotics were considered suspected PIE cases. Eyes were grouped based on preparation with PI or AqCHX.

Main outcome measures: The primary outcomes were incidence of suspected and culture-positive PIE and visual acuity at 3 months post endophthalmitis.

Results: A total of 302,474 intravitreal injections were administered during the study period. Within the PI group, 59 cases of suspected PIE occurred following 267,190 injections (0.022%; 1 in 4,529 injections) compared to 5 cases following 35,284 injections (0.014%; 1 in 7,057 injections) in the AqCHX group (p=0.34). For the PI group, there were 10 culture-positive PIE cases (0.0037%, 1 in 26,719 injections) compared to 0 cases in the AqCHX group (p=0.25). At 3-months post-infection, average visual acuity in the PI group was 0.97 (∼20/200) and 1.4 (∼20/500) in the AqCHX group (p=0.41). When controlling for prefilled syringe status, there was no difference in rates of PIE between antisepsis groups (p=0.23).

Conclusions: The incidence of endophthalmitis following intravitreal injection is low with no difference in the rates of infection with eyes prepared with topical PI compared to AqCHX. Topical AqCHX is a safe and effective antiseptic alternative to PI for the prevention of endophthalmitis following intravitreal injection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信